Hyperfine, Inc. (NASDAQ:HYPR – Get Free Report) has earned a consensus rating of “Hold” from the five brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $1.45.
HYPR has been the topic of several research reports. Zacks Research upgraded Hyperfine to a “hold” rating in a research note on Thursday, March 19th. Lake Street Capital increased their price objective on shares of Hyperfine from $2.00 to $2.50 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Hyperfine in a report on Thursday, January 22nd.
Read Our Latest Analysis on Hyperfine
Institutional Inflows and Outflows
Hyperfine Price Performance
NASDAQ HYPR opened at $1.22 on Friday. The stock has a market capitalization of $118.06 million, a price-to-earnings ratio of -2.76 and a beta of 1.09. Hyperfine has a 1-year low of $0.53 and a 1-year high of $2.22. The business’s fifty day moving average price is $1.16 and its 200-day moving average price is $1.20.
Hyperfine (NASDAQ:HYPR – Get Free Report) last issued its quarterly earnings data on Wednesday, March 18th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $5.29 million during the quarter, compared to analyst estimates of $5.30 million. Hyperfine had a negative return on equity of 95.09% and a negative net margin of 262.29%. Equities research analysts anticipate that Hyperfine will post -0.57 EPS for the current year.
About Hyperfine
Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.
The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.
Featured Stories
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
